Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

(2021) Louisa Maria Bulirsch et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE)

(2020) Justus G. Garweg   KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE

Brolucizumab and immunogenicity

(2020) Ashish Sharma et al.   EYE

HAWK and HARRIER

(2020) Pravin U. Dugel et al.   OPHTHALMOLOGY

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

(2020) Ramin Tadayoni et al.   OPHTHALMOLOGICA

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

(2019) Pravin U. Dugel et al.   OPHTHALMOLOGY

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

(2017) Rita Laiginhas et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial

(2017) Pravin U. Dugel et al.   OPHTHALMOLOGY

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema

(2016) Ehsan Rahimy et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Anti-VEGF Therapy for Retinal Vein Occlusions

(2016) Claudio Campa et al.   CURRENT DRUG TARGETS

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration

(2016) Frank G. Holz et al.   OPHTHALMOLOGY

Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review

(2011) Elena Prokofyeva et al.   OPHTHALMIC RESEARCH